177Lu-PSMA-0057

DRUG2 trials

Sponsors

Nanjing First Hospital, Nanjing Medical University, Chengdu StarRay Therapeutics Co., Ltd

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Prostate Cancer

Early Phase 1

Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer

Nanjing First Hospital, Nanjing Medical UniversityMetastatic Prostate Cancer

Start: 2023-03-01End: 2025-03-01Target: 10Updated: 2023-09-22

Phase 1

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Not yet recruitingNCT07310355

Chengdu StarRay Therapeutics Co., LtdMetastatic Castration-resistant Prostate Cancer (mCRPC)

Start: 2025-12-30End: 2030-04-30Target: 49Updated: 2025-12-30